|
| Study | Pennsaid® therapy | Age (mean (SD)) | Sample (F%) | Areas | Duration (W) | Adverse events (no. (and %) of patients) |
| Application-site skin | Gastrointestinal | Other reaction |
|
| Bookman et al. 2004 [29] | Diclofenac solution, 1.5% (40 drops), 4 times daily | G1: 62.5 (11.7)
G2: 62.1 (11.4) | G1: 84 (62)
G2: 80 (68) | Canada | 4 | G1: 44 (52.38)
G2: 41 (51.25) | G1: 8 (9.52)
G2: 12 (15.00) | G1: 6 (7.14)
G2: 1 (1.25) |
| Roth and Shainhouse 2004 [30] | Diclofenac solution, 1.5% (40 drops), 4 times daily | G1: 63.4 (10.5)
G2: 64.9 (10.6) | G1: 164 (68.9)
G2: 162 (66.7) | USA | 12 | G1: 81 (49.39)
G2: 53 (32.72) | G1: 24 (14.63)
G2: 18 (11.11) | G1: 21 (12.8)
G2: 17 (10.49) |
| Baer et al. 2005 [31] | Diclofenac solution, 1.5% (40 drops), 4 times daily | G1: 65.0 (11.0)
G2: 64.6 (10.9) | G1: 107 (52.3)
G2: 109 (60.6) | Canada | 6 | NR | G1: 12 (11.21)
G2: 6 (5.50) | G1: 12 (11.21)
G2: 12 (11.01) |
| Simon et al. 2009 [21] | Diclofenac solution, 1.5% (40 drops), 4 times daily | G1: 61.7 (9.8)
G2: 62.1 (9.3) | G1: 154 (67.5)
G2: 161 (55.9) | Canada | 12 | G1: 41 (26.62)
G2: 27 (16.77) | G1: 10 (6.49)
G2: 18 (11.18) | G1: 80 (51.95)
G2: 87 (54.04) |
| Wadsworth et al. 2016 [22] | Diclofenac solution, 2% (2 mL), 4 times daily | G1: 60.2 (9.2)
G2: 61.9 (9.1) | G1: 130 (64.6)
G2: 129 (69.8) | USA | 4 | G1: 43 (33.08)
G2: 75 (58.14) | NR | NR |
|
